FINAL PROGRAMME

British HIV Association BHIVA

22nd Annual Conference of the British HIV Association (BHIVA)

19-22 April 2016

Manchester Central, UK

Including Hepatology highlights for the HIV Physician 1830–2030 Tuesday 19 April 2016

www.bhiva.org

#BHIVA2016

18 CPO Credits

Joining forces, changing futures

Please join us on Wednesday 20th April in the Exchange Auditorium, to hear ViiV Healthcare's experts discuss dolutegravir: design, to real world experience.





Healthcare

Prescribing Information

Triumeq[®] dolutegravir 50mg/abacavir 600mg/ lamivudine 300mg tablets See Summary of Product Characteristics before prescribing, Indication: HIV in over 12 years and ≥ 40kg, Screen for HLA-B*5701 prior to use. Do not use if " CONTENT CONTENT of the seed oblivation of the set of the se HLÅ-8*5701 positive. **Dose:** one tablet once daily with or vithout food. *Elderly:* Limited data in 65+ yrs. *Creatinine clearance <50m/min or moderate/severe hepatic impairment.* Not recommended. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/precautions:** Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-8*5701+ or previous suspected abacavir HSR. Stop Triume without delay if HSR suspected. Never reintroduce any dolutegravir- or abacavir-containing product after suspected HSR. Risks of immune reactivation. syndrome,osteonecrosis, increased HLA-B*5701 positive. Dose: one tablet once daily with or reactivation syndrome,osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MI; minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. (with etravirine [without boosted PI], efavirenz, nevirapine, magnetic boosted Vipranavir, carbamazepine, oxcarbazepine, phenytoin, phenobarbital and St John's Wort). Use with cladribine not recommended. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation.

Caution with metformin: monitor renal function and consider metformin dose adjustment. Caution with ribavirin. **Pregnancy/lactation**: Not recommended. Avoid breast-feeding. **Side effects**: See SPC for details. Headache, insomnia, sleep/dream disorders, GI disturbance, fatigue, hypersensitivity, anorexia, depression, dizziness, somolence, lethargy, malaise, cough, nasal symptoms, rash, pruritus, alopecia, arthraigia, muscle disorders, asthenia, fever, elevations of ALT, AST and CPK, blood dyscrasias, suicidal ideation or suicide attempt, rhabdomyolysis, lactic acidosis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. **Basic NHS** costs: 30 tablets: £798.16 EU/1/14/940001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd. from Customer Contact Centre, GlaxoSmithKline UK Ltd Stockley Park West, Uxbridge, Middlesex UB11 1BT. POM

Triumeq is a registered trademark of the ViiV Healthcare Group of Companies Date of approval: February 2016 Zinc code: UK/TRIM/0037/14(4)

Symposium, 22nd Annual BHIVA Conference, 2016

18:00 18:10	Welcome and introduction	Dr Romina Quercia - Chair
18:10 18:30	Joining forces: dolutegravir, designed to deliver	Dr James Demarest
18:30 18:50	Changing futures: dolutegravir, designed for the real world	Dr Andrew Zolopa
18:50 19:00	Q&A	All

Tivicay® Volutegravir 50mg tablets Prescribing Information See Summary of Product Characteristics before prescribing. Indication: HIV in >12 years and see summary or Product Characteristics before prescribing. Indication: HIV in >12 years and ≥40kg as part of combination therapy. **Dosing**: 50mg once daily with or without food if no proven/ suspected integrase resistance. 50mg twice daily with efavirenz, nevirapine, tipranavir/ritonavir, etravirine (without boosted PI), carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John's Wort or rifampicin. Adults with proven/ suspected integrase resistance: 50mg twice daily oreferably Wort or rifampicin. Adults with proven/ suspected integrase resistance: 50mg twice daily preferably with food. *Elderly*. Limited data in 65+ yrs. Caution in severe hepatic impairment. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/precautions:** Risk of hypersensitivity reactions. Discontinue dolutegravir and other suspect agents immune reactivation sudformed Risks of ostenpercrisis immune reactivation sudformed Risks of osteonecrosis, immune reactivation syndrome Monitor LFTs in Hepatitis B/C co-infection and ensure Monitor LF1s in Hepatitis B/C co-infection and ensure effective Hepatitis B therapy. Caution with metformin: monitor renal function and consider metformin dose adjustment. Use with etravirine requires boosted PI or increased dose of dolutegravir. Use with Mg/ AI-containing antacids, calcium, multivitamins or iron requires dosage separation. **Pregnancy/ lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for full details. Headache,

disturbance, insomnia, GI abnormal dreams depression, dizziness, rash, pruritus, fatigue, elevations of ALT, AST and CPK, hypersensitivity, suicidal ideation or suicida attempt. Basic NHS costs: 30 tablets £498.75 EU/1/13/892/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT. POM

Tivicay is a registered trademark of the ViiV Healthcare Group of Companies Date of approval: August 2015 Zinc code: UK/DLG/0055/13(7)

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/vellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.



TRIUMEQ and TIVICAY are trademarks of the ViiV Healthcare group of companies ©ViiV Healthcare group of companies 2015. All rights reserved

UK/DTGP/0004/16a Date of preparation: March 2016







BHIVA Committees	4
Programme Summary	5
Programme	6–14
Satellite Symposia and Sponsors' Lunchtime Workshops	15,16
Exhibition Floor Plan and Exhibitors	
Conference Information	
Conference Scholarships and Awards	
Social Events	21
BHIVA Plenary Speaker Biographies	22–26
Sponsors and Exhibitors	27

Badges must be worn at all times in order to gain access to the lecture theatre, exhibition and catering areas

VENUES AND LOCATIONS

All locations are in Manchester Central, unless stated otherwise

Registration	Exchange Foyer, Level One
Lecture Theatre	Exchange Auditorium, Level One
Exhibition	Exchange Hall, Level One
Posters	Exchange Hall, Level One
Lunch and Refreshments	Exchange Hall, Level One
BHIVA Lunchtime Workshops 1, 3, 5	Exchange Room 1, Level Two
BHIVA Lunchtime Workshops 2, 4	Exchange Room 2 & 3, Level Two
FHIVA Lunchtime Workshop	Exchange Room 2 & 3, Level Two
Satellite Symposia	Exchange Auditorium, Level One
Sponsors' Workshops	Exchange Room 4 & 5, 6 & 7, Level Two
Speakers' Preview Room	Exchange Foyer, Level One
Sponsors' Rehearsal Room	Organiser's Office 2, Exchange Foyer, Level Zero
Civic Welcome Reception	Exchange Hall, Level One
Gala Dinner	Manchester Town Hall

18 CPD Credits Unique reference number: 102242



BHIVA COMMITTEES

BHIVA B	EXECUTIVE COMMITTEE
	OFFICERS
	Chair
Dr D Asboe	Chelsea and Westminster Hospital, London
	Vice Chair
Dr A Palfreeman	Leicester Royal Infirmary
	Honorary Secretary
Dr A de Ruiter	St Thomas' Hospital, London
	Honorary Treasurer
Dr D Churchill	Royal Sussex County Hospital, Brighton
	MEMBERS
Prof B Angus	University of Oxford
Prof M Bower	Chelsea and Westminster Hospital, London
Dr D Chadwick	James Cook University Hospital,
	Middlesbrough
Dr M Chaponda	Royal Liverpool University Hospital
Mr P Clift	UK-CAB Community Representative
Prof L Dorrell	University of Oxford
Dr A Freedman	Cardiff University School of Medicine
Prof B Gazzard CBE	Chelsea and Westminster Hospital, London
Dr Y Gilleece	Royal Sussex County Hospital, Brighton
Prof C Leen	Western General Hospital, Edinburgh
Dr C Orkin	Barts Health NHS Trust, London
Dr I Reeves	Homerton University Hospital, London
Prof C Sabin	University College London
Dr G Schembri	Manchester Centre for Sexual Health
Dr A Sullivan	Chelsea and Westminster Hospital, London
Dr L Waters	Mortimer Market Centre, London



CONFERENCES SUBCOMMITTEE

Dr C Orkin	Chair and BHIVA Executive Committee member
Dr L Waters	Vice Chair and BHIVA Executive Committee member
Dr A Ustianowski	Local Host, BHIVA Annual Conference 2016
Dr D Asboe	BHIVA Executive Committee member
Prof M Bower	BHIVA Executive Committee member
Mr G Brough	Invited Representative
Dr D Churchill	BHIVA Executive Committee member
Dr M Chaponda	BHIVA Executive Committee member
Mr P Clift	BHIVA Executive Committee member and
	Community Representative
Dr A de Ruiter	BHIVA Executive Committee member
Prof B Gazzard CBE	BHIVA Executive Committee member
Prof C Leen	BHIVA Executive Committee member
Mrs S Morris	Invited Representative
	1
Dr A Palfreeman	BHIVA Executive Committee member
Dr A Palfreeman Dr I Reeves	
	BHIVA Executive Committee member
Dr I Reeves	BHIVA Executive Committee member BHIVA Executive Committee member
Dr I Reeves	BHIVA Executive Committee member BHIVA Executive Committee member BHIVA Education and Scientific
Dr I Reeves Prof C Sabin	BHIVA Executive Committee member BHIVA Executive Committee member BHIVA Education and Scientific Subcommittee Chair

ORAL RESEARCH JUDGING PANEL

Dr L Waters (Chair)	Mortimer Market Centre, London
Dr M Chaponda	Royal Liverpool University Hospital
Dr A Ustianowski	North Manchester General Hospital
Dr I Reeves	Homerton University Hospital, London
Prof C Sabin	University College London
Dr A de Ruiter	St Thomas' Hospital London
Dr M Kingston	Central Manchester University Hospitals NHS Foundation Trust
Mrs S Morris	Western General Hospital, Edinburgh

POSTER PRESENTATION JUDGING PANEL

Dr A Palfreeman (Chair)	Leicester Royal Infirmary
Dr D Churchill	Royal Sussex County Hospital, Brighton
Prof L Dorrell	University of Oxford
Dr Y Gilleece	Royal Sussex County Hospital, Brighton
Prof C Leen	Western General Hospital, Edinburgh
Dr C Orkin	Barts Health NHS Trust, London
Dr M Tenant-Flowers	Retired Consultant in HIV and Sexual Health Medicine
Dr G Schembri	Manchester Centre for Sexual Health
Dr G Schembri	Manchester Centre for Sexual Health





TUESDAY 19 APRIL 2016

1730–2030	Registration open at Manchester Central
1830–2030	Hepatology highlights for the HIV Physician

WEDNESDAY 20 APRIL 2016

0800–1900	Registration and Exhibition open at Manchester Central
0900–0910	Welcome Address
0910–1000	BHIVA Plenary Session 1
1000–1100	Janssen Satellite Symposium
1100–1120	Morning coffee
1120–1220	Gilead Sciences Satellite Symposium
1220–1300	BHIVA Review Session
1300–1500	Lunch, Workshops and Poster Presentations
1310–1355	BHIVA Lunchtime Workshops 1 and 2
1355–1455	Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop
1355–1455	Pfizer Lunchtime Workshop
1500–1530	BHIVA Invited Lecture 1
1530–1630	Oral Research Presentations: Session 1
1630–1700	Afternoon tea
1700–1800	BHIVA Plenary Session 2
1800–1900	ViiV Healthcare Satellite Symposium
1900–2000	Civic Welcome Reception

THURSDAY 21 APRIL 2016

0800–1800	Registration and Exhibition open at Manchester Central
0810–0855	SWIFT Workshop
0900–1000	MSD Satellite Symposium
1000–1030	BHIVA Invited Lecture 2
1030–1100	MRC Clinical Trials Unit Session
1100–1130	Morning coffee
1130–1300	Oral Research Presentations: Session 2
1300–1500	Lunch, Workshops and Poster Presentations
1310–1355	BHIVA Lunchtime Workshops 3 and 4
1355–1455	Gilead Sciences Lunchtime Workshop
1355–1455	ViiV Healthcare Lunchtime Workshop
1500–1630	Oral Research Presentations: Session 3
1630–1700	Afternoon tea
1700–1730	BHIVA Audit Session
1730–1830	BHIVA Plenary Session 3
2000–0030	Gala Dinner: Manchester Town Hall

FRIDAY 22 APRIL 2016

0830–1430	Registration and Exhibition open at Manchester Central
0900–1000	Clinico-pathological Case Presentations
1000–1030	BHIVA Keynote Lecture
1030–1100	Morning coffee
1100-1200	Oral Research Presentations: Session 4
1200–1230	Oral Poster Presentations
1230–1430	Lunch, Workshops and Poster Presentations
1240–1325	BHIVA Lunchtime Workshop 5
1240–1325	FHIVA Lunchtime Workshop
1325–1425	MSD Lunchtime Workshop
1430–1445	BHIVA Prizes and Awards Ceremony
1445–1515	BHIVA Invited Lecture 3
1515–1615	BHIVA Plenary Session 4
1615	Close

ANNUAL CONFERENCE PROGRAMME



TUESDAY 19 APRIL 2016

1730–1830	Registration and arrival refreshments
1830–2030	Hepatology highlights for the HIV Physician Exchange Auditorium, Level One
	Supported by 🔿 🖧 🛞 Bristol-Myers Squibb 🌠 GILEAD 📀 MSD
	Sponsors do not have any involvement in speaker selection or content of this session.
1830–1835	Welcome address Chairs: Dr Sanjay Bhagani Royal Free London NHS Foundation Trust Dr Andy Ustianowski North Manchester General Hospital
1840–1915	Update on new and upcoming DAA treatment regimens for HCV Dr Andy Ustianowski North Manchester General Hospital
1915–1945	Short-duration DAA therapy, DAA resistance Dr Graham Cooke Imperial College Healthcare NHS Trust, London
1945–2015	HBV – role of new agents and non-viral liver disease in HIV Dr Patrick Kennedy Barts and The London School of Medicine and Dentistry
2015–2030	Panel Discussion: Availability of DAAs and BHIVA Co-infection treatment guidelines
	WEDNESDAY 20 APRIL 2016
0800–1900	Registration open at Manchester Central
0800–1900	Registration open at Manchester Central ◀ All sessions will be held in Exchange Auditorium unless otherwise stated ►
0800–1900 0900–0910	
	All sessions will be held in Exchange Auditorium unless otherwise stated Welcome Address by the Chair of the British HIV Association Dr David Asboe
0900–0910	 ✓ All sessions will be held in Exchange Auditorium unless otherwise stated ➤ Welcome Address by the Chair of the British HIV Association Dr David Asboe Chelsea and Westminster Hospital, London BHIVA Plenary Session 1 Chairs: Mr Garry Brough
0900–0910	 ▲ All sessions will be held in Exchange Auditorium unless otherwise stated > Welcome Address by the Chair of the British HIV Association Dr David Asboe Chelsea and Westminster Hospital, London BHIVA Plenary Session 1 Chairs: Mr Garry Brough Positively UK Dr Melinda Tenant-Flowers
0900–0910	 ✓ All sessions will be held in Exchange Auditorium unless otherwise stated ➤ Welcome Address by the Chair of the British HIV Association Dr David Asboe Chelsea and Westminster Hospital, London BHIVA Plenary Session 1 Chairs: Mr Garry Brough Positively UK Dr Melinda Tenant-Flowers Retired Consultant in HIV and Sexual Health Financing the NHS and what it means for HIV Dr Nikhil Premchand
0900–0910	 ✓ All sessions will be held in Exchange Auditorium unless otherwise stated ➤ Welcome Address by the Chair of the British HIV Association Dr David Asboe Chelsea and Westminster Hospital, London BHIVA Plenary Session 1 Chairs: Mr Garry Brough Positively UK Dr Melinda Tenant-Flowers Retired Consultant in HIV and Sexual Health Financing the NHS and what it means for HIV Dr Nikhil Premchand Northumbria NHS Trust Where we are right now: Commissioning HCV treatment and PrEP Dr David Asboe
0900–0910	 ✓ All sessions will be held in Exchange Auditorium unless otherwise stated > Welcome Address by the Chair of the British HIV Association Dr David Asboe Chelsea and Westminster Hospital, London BHIVA Plenary Session 1 Chairs: Mr Garry Brough Positively UK Dr Melinda Tenant-Flowers Retired Consultant in HIV and Sexual Health Financing the NHS and what it means for HIV Dr Nikhil Premchand Northumbria NHS Trust Where we are right now: Commissioning HCV treatment and PrEP Dr David Asboe Chelsea and Westminster Hospital, London Dr Andy Ustianowski
0900–0910 0910–1000	 ✓ All sessions will be held in Exchange Auditorium unless otherwise stated > Welcome Address by the Chair of the British HIV Association Dr David Asboe Chelsea and Westminster Hospital, London BHIVA Plenary Session 1 Chairs: Mr Garry Brough Positively UK Dr Melinda Tenant-Flowers Retired Consultant in HIV and Sexual Health Financing the NHS and what it means for HIV Dr Nikhil Premchand Northumbria NHS Trust Where we are right now: Commissioning HCV treatment and PrEP Dr David Asboe Chelsea and Westminster Hospital, London Dr Javid Asboe Chelsea and Westminster Hospital, London Dr David Asboe Chelsea and Westminster Hospital, London Dr Andy Ustianowski North Manchester General Hospital

Manchester · 2016 ANNUAL CONFERENCE PROGRAMME



	WEDNESDAY 20 APRIL 2016
	 All sessions will be held in Exchange Auditorium unless otherwise stated
1220–1300	BHIVA Review Session Chair: Dr Duncan Churchill Royal Sussex County Hospital, Brighton
	Translating recent research into clinical practice Dr lain Reeves Homerton University Hospital, London
1300–1500	Lunch, Workshops and Poster Presentations
1310–1355	BHIVA Lunchtime Workshop 1 Exchange Room 1, Level Two Difficult pharmacology case presentations Chairs: Dr Marta Boffito Chelsea and Westminster Hospital, London
	Professor Saye Khoo University of Liverpool
	Polypharmacy & polypathology Dr Alessia Dalla Pria Chelsea and Westminster Hospital, London
	A little bit of luck goes a long way Dr Sally Jewsbury Central Manchester NHS Foundation Trust
	Past-pointing at the diagnosis Dr Mimie Chirwa Chelsea and Westminster Hospital, London
1310–1355	BHIVA Lunchtime Workshop 2 Exchange Room 2 & 3, Level Two Chair: Mr Paul Clift King's College Hospital NHS Foundation Trust, London
	UK-CAB Community Workshop: What does HIV-positive mean in an age of virus undetectability
	Ms Fabiola Bayavuge Black Health Agency (BHA)
	Mr Robert James Birchgrove
	Dr Iain Reeves Homerton University Hospital, London
	Dr Lisa Thorley UK Community Advisory Board
1355–1455	Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop Exchange Room 4 & 5, Level Two (see page 15 for further information)
1355–1455	Pfizer Lunchtime Workshop Exchange Room 6 & 7, Level Two (please see page 15 for further information)
1500–1530	BHIVA Invited Lecture 1 Chair: Dr Annemiek de Ruiter St Thomas' Hospital, London
	HIV in Eastern Europe Dr Claire Thorne UCL Institute of Child Health, London

ANNUAL CONFERENCE PROGRAMME



	WEDNESDAY 20 APRIL 2016
1530–1630	Oral Research Presentations: Session 1 HIV care and service development Chairs: Professor Caroline Sabin University College London Dr Gabriel Schembri Manchester Centre for Sexual Health
	1530–1540 Abstract O1 Non-AIDS mortality among people diagnosed with HIV in the era of highly-active antiretroviral therapy compared to the general population: England and Wales, 1997–2012 <i>Miss Sara Croxford, Public Health England</i>
	1540–1550 Abstract O2 Quality of HIV care in the United Kingdom is excellent and improving: over 80% of diagnosed patients are virologically suppressed Dr Valerie Delpech, Public Health England
	1550–1600 Abstract O3 A national nurse-led audit of the standards for psychological support for adults living with HIV Miss Michelle Croston, North Manchester General Hospital
	1600–1610 Abstract O4 Managing the menopause in women living with HIV: a survey of general practitioners and practice nurses Dr Mimie Chirwa, Chelsea and Westminster Hospital, London
	1610–1620 Abstract O5 HIV treatment information and advocacy 2014/15: continued demand for community support services Mr Robin Jakob, HIV i-Base
	1620–1630 Abstract O6 HIV stigma and discrimination in primary care Dr John Forni, ViiV Healthcare UK Ltd
1630–1700	Afternoon Tea
1700–1800	BHIVA Plenary Session 2 Chairs: Mrs Sheila Morris Western General Hospital, Edinburgh
	Dr Ed Wilkins North Manchester General Hospital
	Cost-effectiveness of ART as prevention Dr Valentina Cambiano University College London
	Testing strategies for HIV and HCV: similarities and differences? Dr Chloe Orkin Barts Health NHS Trust, London
1800–1900	ViiV Healthcare UK Satellite Symposium (please see page 16 for further information)
1900–2000	Civic Welcome Reception (please see page 21 for further details) Exchange Hall, Level One, Manchester Central

Manchester · 2016 ANNUAL CONFERENCE PROGRAMME



THURSDAY 21 APRIL 2016

0800–1800	Registration open at Manchester Central
	◄ All sessions will be held in Exchange Auditorium unless otherwise stated ►
0810–0855	Supporting Women with HIV Information Network (SWIFT) Workshop Exchange Room 1, Level Two Chair: Dr Yvonne Gilleece Royal Sussex County Hospital, Brighton The future for women living with HIV Dr Yvonne Gilleece Royal Sussex County Hospital, Brighton Miss Laura Kwardem Ourspace, Peterborough Miss Angelina Namiba Salamander Trust
	Dr Shema Tariq Mortimer Market Centre, London
0900–1000	MSD Ltd Satellite Symposium (please see page 16 for further information)
1000–1030	BHIVA Invited Lecture 2 Chair: Dr Laura Waters Mortimer Market Centre, London
	Anal cancer prevention strategies including screening for HPV-related diseases in HIV-positive patients Professor Charles Lacey University of York
1030–1100	MRC Clinical Trials Unit Session Chair: Dr Ian Williams Central & North West London NHS Foundation Trust
	Evidence from the START trial and sub-studies: impact of early ART initiation on end-organ disease and other serious non-AIDS-defining conditions Dr Alejandro Arenas-Pinto MRC Clinical Trials Unit, London
1100–1130	Morning Coffee
1130–1300	Oral Research Presentations: Session 2
	Clinical and pathological Chairs: Professor Mark Bower Chelsea and Westminster Hospital, London Professor Clifford Leen Western General Hospital, Edinburgh
	1130–1140 Abstract O7 Outcomes of autologous stem cell transplantation in patients with relapsed/refractory HIV- associated lymphoma Dr Ramya Ramaswami, Chelsea and Westminster Hospital, London
	1140–1150 Abstract O8 HPV vaccination acceptability, uptake and completion in younger men who have sex with men in an HIV-positive cohort Dr John McSorley, London North West Healthcare NHS Trust
	1150–1200 Abstract O9 Prevalence, type and factors associated with HPV infection at multiple sites in young HIV- positive MSM Dr Corinna Sadlier, St James's Hospital, Dublin, Ireland

ANNUAL CONFERENCE PROGRAMME



THURSDAY 21 APRIL 2016

	1200–1210 Abstract O10 Healthy HIV-1-seropositive individuals have impaired alveolar immunity despite highly active antiretroviral therapy Dr Paul Collini, University of Sheffield
	1210–1220 Abstract O11 Interventions to improve screening for latent TB: effectiveness and outcomes Dr Karen Rogstad, Sheffield Teaching Hospitals NHS Foundation Trust
	1220–1230 Abstract O12 Brain MRI changes associated with poorer cognitive function despite suppressive antiretroviral therapy Dr Jonathan Underwood, Imperial College London
	1230–1240 Abstract O13 What is the overlap between HIV and shigellosis epidemics in England? Dr Keerthi Mohan, Public Health England
	1240–1250 Abstract O14 Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection Professor Mark Nelson, Chelsea and Westminster Hospital, London
	1250–1300 Abstract O15 Relapse of multicentric Castleman's disease following rituximab-based therapy in 82 PLWH Dr Alessia Dalla Pria, Chelsea and Westminster Hospital, London
1300–1500	Lunch, Workshops and Poster Presentations
1310–1355	BHIVA Lunchtime Workshop 3 Exchange Room 1, Level Two Chair: Dr Orla McQuillan Central Manchester University Hospitals NHS Foundation Trust
	HIV Clinical Dashboard Dr Valerie Delpech Public Health England
1310–1355	BHIVA Lunchtime Workshop 4 Exchange Room 2 & 3, Level Two Chair: Dr Mas Chaponda Royal Liverpool University Hospital
	Contributing to the peer community: what are the opportunities and challenges for new consultants?
	The path from Consultant to research, mobile apps, Chair of website working group Dr Gabriel Schembri Manchester Centre for Sexual Health
	The path from Consultant to Conferences Subcommitte Chair Dr Chloe Orkin Barts Health NHS Trust, London
	The path from Consultant to research Dr Julie Fox Guy's & St Thomas' NHS Foundation Trust, London
1355–1455	Gilead Sciences Lunchtime Workshop Exchange Room 4 & 5, Level Two (please see page 16 for further information)
1355–1455	ViiV Healthcare UK Lunchtime Workshop Exchange Room 6 & 7, Level Two (please see page 16 for further information)



THURSDAY 21 APRIL 2016

1500–1630	Oral Research Presentations: Session 3
	HIV testing and prevention Chairs: Dr Orla McQuillan Central Manchester University Hospitals NHS Foundation Trust
	Dr Ann Sullivan Chelsea and Westminster Hospital, London
	1500–1510 Abstract O16 Does the new migrant "jungle" camp in Calais meet the minimum standards for sexual and reproductive health in an emergency situation set down by the inter-agency working group (IAWG) in reproductive health? Dr Fionnuala Finnerty, Brighton & Sussex University Hospitals NHS Trust
	1510–1520 Abstract O17 Factors associated with undiagnosed HIV infection among people who inject drugs in England, Wales and Northern Ireland, 2005–2014 Dr Vivian D Hope, Public Health England
	1520–1530 Abstract O18 Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission <i>Ms Marina Daskalopoulou, University College London</i>
	1530–1540 Abstract O19 Self-testing for HIV: initial experience of the UK's first kit Dr Michael Brady, King's College Hospital, London
	1540–1550 Abstract O20 Are laboratory specialties recommending HIV testing for suggestive results and is anyone listening? Dr Owen Seddon, University Hospital of Wales, Cardiff
	1550–1600 Abstract O21 Reducing the barriers to HIV testing – a simplified consent pathway increases the uptake of HIV testing in a high-prevalence population Mr Joel Paparello, Guy's and St Thomas' NHS Foundation Trust, London
	1600–1610 Abstract O22 A calculation of the financial impact of opt-out HIV testing in a London Emergency Department (ED) Dr Hannah Alexander, King's College Hospital, London
	1610–1620 Abstract O23 The Pre-exposure Prophylaxis (PrEP) Clinic at a central London sexual health service – the first 6 weeks Dr Martina Toby, Chelsea and Westminster Hospital, London
	1620–1630 Abstract O24 Baseline predictors of HIV Infection in the no-PrEP group in the PROUD trial Dr Monica Desai, Public Health England
1630–1700	Afternoon Tea
1700–1730	BHIVA Audit Session Chair: Dr Andrew Freedman Cardiff University School of Medicine
	Does adjustment for patient mix affect the results of the BHIVA National Audit 2015? Professor Margaret May University of Bristol

ANNUAL CONFERENCE PROGRAMME

	THURSDAY 21 APRIL 2016
1730–1830	BHIVA Plenary Session 3 Chairs: Dr Iain Reeves Homerton University Hospital, London Dr Andy Ustianowski North Manchester General Hospital
	Managing steroids and antiretroviral therapy Dr Laura Waters Mortimer Market Centre, London
	HIV and the lung: bronchiectasis, COPD, LIP – the facts Dr Rashida Ferrand Biomedical Research and Training Institute, Harare, Zimbabwe
	NAFLD (Non-alcoholic fatty liver disease): an emerging problem Dr Lucy Garvey Imperial College Healthcare NHS Trust, London
	This educational session is funded by an independent educational grant from ViiV Healthcare. ViiV Healthcare does not have any involvement in speaker selection or content of this session.
1945	Drinks Reception and Gala Dinner (please see page 21 for further details) Manchester Town Hall
	FRIDAY 22 APRIL 2016
0830–1430	Registration open at Manchester Central
	\blacktriangleleft All sessions will be held in Exchange Auditorium unless otherwise stated \blacktriangleright
0900–1000	Clinico-pathological Case Presentations Chairs: Professor Sebastian Lucas Guy's and St Thomas' Hospital NHS Foundation Trust, London
	Dr Ula Mahadeva Guy's and St Thomas' Hospital NHS Foundation Trust, London
	An unusual cause of abdominal swelling in an HIV-positive man Dr Amy Baggot Leeds Teaching Hospitals NHS Trust
	IL6 be damned! Dr Charles Williams St George's Healthcare NHS Trust, London
	A difficult case of encephalitis Dr Alvin Sornum Imperial College Healthcare NHS Trust, London
	Lymphadenopathy, HIV test or FNA first? Dr Rebecca Thomson-Glover Countess of Chester Hospital NHS Trust
1000–1030	BHIVA Keynote Lecture Chair: Dr Chloe Orkin Barts Health NHS Trust, London
	DIY testing Dr Alison Rodger University College London
	Dr Michael Brady King's College Hospital, London

British HIV Association BHIVA

Manchester · 2016 ANNUAL CONFERENCE PROGRAMME



	FRIDAY 22 APRIL 2016
1030–1100	Morning Coffee
1100–1200	Oral Research Presentations: Session 4
	Antiretroviral therapy Chairs: Dr David Chadwick James Cook University Hospital, Middlesbrough Professor Lucy Dorrell University of Oxford
	1100–1110 Abstract O25 Impact of timing of ART on HIV DNA; findings from HEATHER, an observational cohort study Dr John Thornhill, Imperial College London
	1110–1120 Abstract O26 Factors associated with virological rebound in patients receiving protease inhibitor monotherapy in the PIVOT trial Professor David Dunn, MRC Clinical Trials Unit at UCL
	1120–1130 Abstract O27 Impact of regional ARV prescribing guidance on choice of first-line therapy Mr Neal Marshall, Royal Free London NHS Foundation Trust
	1130–1140 Abstract O28 Cost impact of an HIV MDT for managing anti-retroviral switch Dr Farnaz Dave, North Manchester General Hospital
	1140–1150 Abstract O29 Reducing prescribing errors in a large HIV outpatient clinic using feedback strategies to improve prescribers' awareness of their prescribing behaviour <i>Mr Asim Ali, Guy's and St Thomas' NHS Foundation Trust, London</i>
	1150–1200 Abstract O30 Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: a multicentre retrospective cohort study Dr Joseph Lewis, Royal Liverpool University Hospital
1200–1230	Oral Poster Presentations
	Chairs: Dr Adrian Palfreeman Leicester Royal Infirmary
	Dr Laura Waters Mortimer Market Centre, London
1230–1430	Lunch, Workshops and Poster Presentations
1240–1325	BHIVA Lunchtime Workshop 5 Exchange Room 1, Level Two Chairs: Dr Margaret Kingston Central Manchester University Hospitals NHS Foundation Trust Dr Nicola Mackie
	Imperial College Healthcare NHS Trust, London
	Pregnancy and breastfeeding case presentations HIV-2: what to do? Dr Adam Croucher Homerton University Hospital, London
	Always best to double check! Dr Elizabeth Williams Barts Health NHS Trust, London



ANNUAL CONFERENCE PROGRAMME

FRIDAY 22 APRIL 2016

	Livering on the edge Dr Adele Wolujewicz Liverpool Centre for Sexual Health
1240–1325	FHIVA Lunchtime Workshop Exchange Room 2 & 3 Level Two Chair: Dr David Asboe Chelsea and Westminster Hospital, London
	Managing HIV in people with cognitive deficit Dr Alexander Margetts Central and North West London NHS Foundation Trust
	Ms Esther McDonnell Chelsea and Westminster Hospital, London
	Mr Shaun Watson Chelsea and Westminster Hospital, London
1325–1425	MSD Lunchtime Workshop Exchange Room 4 & 5 (please see page 16 for further information)
1430–1445	BHIVA Prizes and Awards Ceremony Chairs: Dr David Asboe Chelsea and Westminster Hospital, London
	Dr Adrian Palfreeman Leicester Royal Infirmary
1445–1515	BHIVA Invited Lecture 3 Chair: Dr Adrian Palfreeman Leicester Royal Infirmary
	New approaches to limit immune activation Dr Turner Overton University of Alabama at Birmingham, USA
	This educational lecture is funded by an independent educational grant from ViiV Healthcare. ViiV Healthcare does not have any involvement in speaker selection or content of this lecture.
1515–1615	BHIVA Plenary Session 4 Chairs: Dr Katherine Ajdukiewicz North Manchester General Hospital
	Professor Brian Angus University of Oxford
	Role of nucleoside-sparing approaches Professor Mark Nelson Chelsea and Westminster Hospital, London
	Emerging toxicities of antiretroviral therapy Dr Duncan Churchill Royal Sussex County Hospital, Brighton
1615	Close by the Chair of the British HIV Association Dr David Asboe Chelsea and Westminster Hospital, London



SATELLITE SYMPOSIA AND SPONSORS' LUNCHTIME WORKSHOPS

	WEDNESDAY 20 APRIL 2016
	All Satellite Symposia will be held in Exchange Auditorium and Sponsors' workshops will be held in Exchange Room 4 & 5 and 6 & 7
1000–1100	Janssen Satellite Symposium NRTI minimisation? – Evidence review and a scientific exchange Dr Ed Wilkins North Manchester General Hospital, UK Dr Chloe Orkin Barts Health NHS Trust, London
1120–1220	Gilead Sciences Satellite Symposium
	Stepping beyond: Managing tomorrow's HIV patients today
	The 216,262,500-step journey Considerations for a long and healthy life with HIV Dr Anton Pozniak Chelsea and Westminster Hospital, London
	Changing pace Exploring the current treatment paradigm Dr Mas Chaponda Royal Liverpool University Hospital
	Stepping beyond today Novel therapies and patient outcomes in the real world Dr Anthony Mills Tony Mills Medical Practice, Los Angeles, California, USA
1355–1455	Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop Exchange Room 4 & 5, Level Two HIV/HCV co-infection: the way forward
	Chair: Dr Sanjay Bhagani Royal Free London NHS Foundation Trust
	Disease and treatment evolution in HIV/HCV co-infection Professor Clifford Leen Western General Hospital, Edinburgh
	Current recommendations – evidence from clinical trials and real-world data Dr Yvonne Gilleece Royal Sussex County Hospital, Brighton
	The importance of DDIs in clinical practice Professor David Back University of Liverpool, UK
1355–1455	Pfizer Lunchtime Workshop Exchange Room 6 & 7, Level Two The Great Debate: Optimising access to vaccination
	Chair: Professor Anna Maria Geretti University of Liverpool
	Guest speakers from primary and secondary care
	This workshop is organised and funded by Pfizer Ltd.



SATELLITE SYMPOSIA AND SPONSORS' LUNCHTIME WORKSHOPS


WEDNESDAY 20 APRIL 2016

1800–1900	ViiV Healthcare UK Satellite Symposium
	Joining forces, changing futures
	Welcome and introduction Chair: Dr Romina Quercia <i>ViiV Healthcare</i>
	Joining forces: dolutegravir, designed to deliver Dr James Demarest <i>ViiV Healthcare</i>
	Changing futures: dolutegravir, designed for the real world Dr Andrew Zolopa <i>ViiV Healthcare</i>

THURSDAY 21 APRIL 2016

0900–1000	MSD Satellite Symposium
	The Great ART debate
	Chair: Jonathan Dimbleby
	Broadcaster
	Panel: Dr Marta Boffito
	Chelsea and Westminster Hospital, London
	Dr Mark Lawton
	Royal Liverpool University Hospital
	Professor Mark Nelson
	Chelsea and Westminster Hospital, London
	Dr Andrew Ustianowski
	North Manchester General Hospital
	Dr Laura Waters
	Mortimer Market Centre, London
1355–1455	Gilead Sciences Lunchtime Workshop Exchange Room 4 & 5, Level Two
	Getting to the bones of it - Bone health: What you need to know
	Chair: Dr Alan Winston
	Imperial College Healthcare NHS Trust, London
	Speaker: Dr Karen Walker-Bone
	University of Southampton
1355–1455	ViiV Healthcare UK Lunchtime Workshop Exchange Room 6 & 7, Level Two
	HIV in 2016: Where's the pill for societal stigma?
	Chair: Mr Robert Fieldhouse
	BASELINE
	This workshop will consist of five people living with HIV in the UK
	FRIDAY 22 APRIL 2016
1325–1425	MSD Lunchtime Workshop Exchange Room 4 & 5, Level Two
	From ideas to implementation: Improving the HIV patient pathway
	Led by Paul Dawson, Fluxx

Manchester · 2016 EXHIBITION FLOOR PLAN AND EXHIBITORS



EXHIBITORS

- 1 ViiV Healthcare UK Ltd
- 2 ViiV Healthcare UK Ltd (Medical)
- 3 MSD Ltd
- 4 Pfizer Ltd
- 5 Children's HIV Association (CHIVA)
- 6 HIV i-Base and UK Community Advisory Board (UK-CAB)
- 7 Gilead Sciences Ltd
- 8 Naz Project London
- 9 Public Health England
- 10 Mildmay Mission Hospital
- 11 Saving Lives
- 12 National HIV Nurses Association (NHIVNA)
- 13 Positively UK
- 14 The Sophia Forum

- 15 Hologic Ltd
- 16 6PM and 6PM Blithe
- 17 Janssen
- 18 Bristol-Myers Squibb Pharmaceuticals Ltd
- **19** Terrence Higgins Trust
- 20 BASELINE
- 21 HIV Pharmacy Association (HIVPA)
- 22 African Health Policy Network
- 23 Dietitians in HIV/AIDS (DHIVA) & Rehabilitation in HIV Association (RHIVA)
- 24 The Sussex Beacon
- 25 National AIDS Trust
- 26 NAM
- 27 Cepheid

British HIV Association

BHIVA



Manchester Central

Windmill Street · Manchester · M2 3GX

Telephone: +44 (0)161 834 2700 · www.manchestercentral.co.uk

Registration

Registration includes access to all scientific sessions, including satellite symposia, the exhibition area, refreshments and lunch for the days specified in your registration acknowledgement correspondence.

Delegate badges

Badges must be worn at all times to gain access to the lecture theatre, catering and exhibition areas. The delegate lanyards have been sponsored by Gilead Sciences.

Accompanying persons Pre-booked and paid only

Accompanying persons' fees include attendance at the Civic Welcome Reception and Gala Dinner. Each event is individually priced. These tickets must have been requested and paid for in advance of the conference. Please note that these fees do not cover attendance at the scientific sessions, exhibition or catering areas of the conference.

BHIVA Lunchtime Workshops

Places are limited and will be restricted to 80 delegates per workshop. Places at each workshop will be available onsite, on a first-come, firstserved basis, at the door of the Lunchtime Workshop. Doors will open 15 minutes prior to the start of each workshop. Each workshop will begin promptly and lunch packs will be provided for delegates attending these sessions, where indicated.

Hepatology highlights for the HIV Physician

For the first time, BHIVA will be holding an HIV and Hepatitis Co-infection session from 1830–2030 on Tuesday 19 April 2016, covering the hepatology highlights from AASLD/EASL.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, pharmaceutical-supported sessions and social events). The unique reference code for the conference is 102242. The entire conference has been allocated 18 CPD credits. Please be advised that the attendance list of the conference will be forwarded to the Royal College of Physicians upon request.

Social events

18

There are two social events: a Civic Welcome Reception (Wednesday) to be held at Manchester Central and a Gala Dinner (Thursday) to be held at Manchester Town Hall. You will require a ticket to gain entry to the Gala Dinner. Please refer to page 21 of this programme for full details of the social events. If you have reserved a ticket but find that you cannot attend, please let the Conference Organiser know as soon as possible and return your ticket to the Registration Desk at your earliest convenience.

Poster presentations

All poster boards will be numbered and poster presenters should use the board displaying the number allocated to their poster. The poster judges will review the posters and subsequently select 15 posters to be highly commended, out of which six will be presented as part of the Oral Research Poster Presentations session at 1200–1230 on Friday 22 April. Poster presenters are required to prepare a few slides prior to the conference to highlight the main points of their poster. We would encourage all poster presenters to check the Registration notice board at 1730 on Thursday 21 April to see whether they have been selected. The BHIVA Ian Williams Best Poster prize will be awarded at the Prizes and Awards Ceremony on Friday 22 April at 1430–1445.

CONFERENCE INFORMATION

Oral research presentations

Oral research presenters are reminded to ensure they bring their oral research presentation slides to the conference in addition to sending them to the Conference Organisers in advance. Any slides must be passed to the audio-visual technicians in the Speakers' Preview Area located in the Exchange Foyer, Level One in good time for their session (minimum 3 hours in advance). Oral research presenters may make use of the Speakers' Preview Area to review their slides prior to presentation. The BHIVA Margaret Johnson Best Oral Presentation prize will be awarded at the Prizes and Awards Ceremony on Friday 22 April at 1430–1445.

Accommodation

Please note that the registration fee does not include accommodation. If you have not already arranged accommodation you can do so by referring to the conference website for further details. It is very important to book accommodation early as rates will increase significantly nearer the time of conference.

WiFi

Free WiFi access will be available throughout the conference venue.

Cloakroom

A manned cloakroom is available onsite at the Exchange Foyer, Level Zero of Manchester Central. All belongings are left at the owner's risk. The British HIV Association does not accept responsibility for the loss of, or damage to, delegates' personal property stored in the cloakroom area.

Exhibition

The exhibition represents an integral element of the conference, providing participants with an excellent platform for networking as well as an opportunity to gain further insight into cutting-edge technology, the latest healthcare solutions, and services within the field of HIV and GU medicine. Entrance to the exhibition hall is free for all registered delegates.

Filming and photography

Please note that all BHIVA sessions held in the lecture theatre (Exchange Auditorium) will be filmed and uploaded to the BHIVA websites following the event. In addition, some still photography will take place at the conference. This will include general coverage of registration, exhibition and workshop areas, as well as conference social events. This material may be published in BHIVA publications or on the BHIVA website.



Manchester Central, UK 19–22 April 2016

British HIV Association

BHIIVA



The BHIVA Margaret Johnson Best Oral Research Presentation

This prize will be awarded to the presenter of the best oral research presentation during the conference. All oral research presentations will be judged by a BHIVA-appointed oral research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 22 April.

The BHIVA Ian Williams Best Poster Presentation

This prize will be awarded to the presenter of the best poster research presentation during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 22 April.

The BHIVA Best Case Presentation

A prize will be awarded to the presenter of the best case presentation as part of the BHIVA Lunchtime Clinico-pathological, Difficult pharmacology, and Pregnancy and breastfeeding case presentations workshops. The prizes will be presented at the Prizes and Awards Ceremony on Friday 22 April.

Commended Oral Presentations

Up to three awards will be presented in recognition of the best oral research presentations during the conference. To be eligible for these prizes the presenter must be of junior grade (sub-consultant or equivalent). All oral presentations will be judged by a BHIVA-appointed oral research judging panel. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 22 April.

Commended Poster Presentations

Up to 15 awards will be presented in recognition of the best poster research presentations during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel. The prizes will be awarded at the end of Thursday 21 April. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 22 April.

Mediscript Awards in collaboration with BHIVA

Two prizes will be awarded for the best oral or poster research presentation during the conference in the field of social sciences and community-based work. The awards will be presented at the Prizes and Awards Ceremony on Friday 22 April.

BHIVA Science Scholarships

Science Scholarships have been awarded to 10 researchers and scientists whose abstracts have been accepted for presentation. All registration fees, a contribution towards travel expenses and accommodation costs are paid by BHIVA to successful candidates.

BHIVA Registration Scholarships

Registration Scholarships have been awarded to up to 10 delegates who are either healthcare professionals who are retired, not working, or employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or postgraduate work. The scholarship covers the conference registration fee.

BHIVA Community Registration Support

BHIVA has supported the registrations of approximately 40 delegates from community organisations in order to assist them with attending the conference.

BHIVA Community Scholarships

Community Scholarships have been awarded to 12 UK-based community registrants to assist them to attend the conference. For those applicants selected, all registration fees and a contribution towards expenses and accommodation costs are paid by BHIVA.

BHIVA Registration Scholarships in collaboration with ViiV Healthcare UK

ViiV Healthcare in collaboration with the British HIV Association (BHIVA) have supported 28 scholarships to assist healthcare professionals (BHIVA members) to attend the 22nd Annual BHIVA Conference, covering the delegate's conference registration fee. The winners were allocated by BHIVA on a first-come, first-served basis.

BHIVA Junior Registration Scholarships

BHIVA have supported 30 registration scholarships for UK-based non-consultant healthcare professionals who work in the field of HIV medicine. Applications were invited from junior doctors, nurses (Band 1-4), junior pharmacists and non-clinical junior researchers to attend the 22nd Annual BHIVA Conference. The scholarship covers a delegate's conference registration fee.



Civic Welcome Reception

Manchester Central

Wednesday 20 April 2016: 1900-2000

Anchester Central is an award-winning venue in the heart of one of Europe's most vibrant cities, converted from the former Manchester Central railway station. Its vaulted arches and station clock have made Manchester Central an iconic city feature for over 130 years. With the capacity to handle intimate corporate functions and large-scale conferences or exhibitions, the historic architecture and state-of-the-art facilities provide the perfect venue for some of the world's leading events.

We are honoured that the Lord Mayor, Councillor Paul Murphy OBE, has kindly agreed to speak and officially welcome delegates to the city.

The Civic Welcome Reception will begin with some short speeches in the exhibition area (Exchange Hall) followed by an opportunity for delegates to network whilst enjoying a drink and some light refreshments.

Gala Dinner

Dress code: Gentlemen are requested to wear jacket and tie

Manchester Town Hall

Thursday 21 April 2016: 1945-0030

Manchester Town Hall in Albert Square is one of the most iconic landmarks in the heart of the city. Regarded as one of the finest examples of Neo-Gothic architecture in the United Kingdom, it is one of the most important Grade 1 listed buildings in England. The building was designed by architect Alfred Waterhouse and was completed in 1877. It contains many grand ceremonial rooms, such as the Great Hall, which is decorated with murals by Ford Madox Brown that illustrate the history of the city.

The Gala Dinner will commence with a drinks reception followed by dinner in the Great Hall. After some short speeches, entertainment will include music by Manchester-based band The Audiopimps, who are set to entertain with a lively mixture of current pop-rock and classic party tunes.



Programme of events

Programme of events

2000

Ticket required

1900–1920 Drinks and Canapés

1940–2000 Drinks and Canapés

Close

1920–1940 Welcome Address and Speeches

- Drinks Reception
- Dinner
- Speeches
- Entertainment, music and dancing



Alejandro Arenas-Pinto is a Senior Clinical Research Associate in the UCL Research Department of Infection and Population Health and MRC Clinical Trials Unit at UCL. Trained in Infectious Diseases and Tropical Medicine in Venezuela and the UK, he completed his PhD in 2006 at UCL. Since 2007 he has been involved in a number of national and international clinical trials on HIV treatment. Currently, Alejandro is Chief Investigator for the START trial and all substudies in the UK as well as Medical Officer for the London ICC and protocol team member.

David Asboe is Clinical Director of HIV Medicine and Sexual Health at Chelsea and Westminster Hospital, London. He has been Chair of the British HIV Association since 2013 and is also Convenor of the Diploma in HIV Medicine examination run by the Worshipful Society of Apothecaries.

Fabiola Bayavuge is a Black African working with BHA for Equality in Health and Social Care as a community development and engagement worker. Her experience is in HIV support and advice, HIV prevention within Black and minority ethnics, HIV prevention in England within Black African communities and in French-English HIV prevention helpline advice. Fabiola is a member of a national HIV treatment advocacy group called UK-CAB and holds an MSC in Public Health.

Sanjay Bhagani is a Consultant Physician in Infectious Diseases and HIV Medicine at the Royal Free Hospital, London and Honorary Senior Lecturer in Infectious Diseases at University College London. After completing his postgraduate training in Infectious Diseases and Internal Medicine in London, he joined the Royal Free Hospital as a Consultant Physician, where he established and is the current lead of a multi-disciplinary HIV/hepatitis co-infection service. This is a tertiary referral service at the forefront of service delivery in all aspects of HIV/viral hepatitis co-infection, ranging from access to Phase 2/3 clinical trials for new agents to joint liver transplant assessment and post-transplant care. His team's research interests include epidemiological, virological and clinical aspects of acute HCV amongst HIV-positive MSM; use of non-invasive tests for liver assessment in resource-rich and resource-limited settings; implementation and clinical research in the management of viral hepatitis and HIV co-infection in resource-limited settings; and Phase 2/3 clinical trials for new agents for treating HCV and HBV. Sanjay is the current Chair of the British HIV Association's Viral Hepatitis Group and serves on the HIV/hepatitis guidelines subcommittees for both the British HIV Association and the European AIDS Clinical Society. He serves on the editorial boards of *AIDS Research and Therapy* and *BMC Hepatology, Medicine and Policy* and is a trustee at AIDSOrphan.

Marta Boffito trained in General Medicine and Infectious Diseases at the Universities of Turin, Italy and San Francisco, USA. She obtained her PhD in 2004 at the University of Liverpool with a thesis on the pharmacokinetics and pharmacodynamics of antiretroviral therapy. Currently, she is a Consultant Physician (Chelsea and Westminster Hospital), Clinical Lead in Clinical Trials (St. Stephen's AIDS Trust), and a Reader (Imperial College), where, in addition to her clinical duties, she is heavily involved in numerous research projects.

Michael Brady is a Consultant in Sexual Health and HIV at King's College Hospital, London and the Medical Director for Terrence Higgins Trust. He has a particular interest in HIV testing, prevention and transmission and has been involved in a number projects to develop and evaluate novel HIV testing strategies including community and outreach point of care testing, on-line home HIV and STI sampling, and HIV self-testing.

Valentina Cambiano is a Research Statistician in the HIV Epidemiology and Biostatistics Group led by Professor Andrew Phillips and Professor Caroline Sabin, within the Department of Infection and Population Health, University College London. She received her MSc in Biostatistics at the University of Milano-Bicocca and she completed her PhD at University College London. Her research interests include modelling HIV epidemics, to investigate the impact of improvements in HIV testing, earlier ART initiation, use of oral PrEP and introduction of new diagnostics.

Duncan Churchill has been a Consultant at the Royal Sussex County Hospital in Brighton since 1999. He trained at Oxford University and at the Middlesex Hospital Medical School, and trained in HIV Medicine at the Middlesex and St Mary's Hospitals. He is currently Honorary Treasurer of BHIVA, Chair of the BHIVA Guidelines subcommittee, and past Chair of the Antiretroviral guidelines writing group.

Graham Cooke is a Clinical Academic based at the St Mary's Campus of Imperial College London. He is Lead for the Clinical Workstream of the MRC-funded Stratified Medicine Programme in Hepatitis C and Chief Investigator on the STOPHCV-1 trial. He has a research programme which covers diagnostic development and evaluation, epidemiology and informatics in relation to HIV and HCV.



Valerie Delpech is a Medical Epidemiologist based at Public Health England and leads a team of scientists and data managers to monitor the HIV epidemic and quality of care people living with HIV receive in the United Kingdom. Valerie's research interests focus on better understanding the epidemiology of HIV and STIs, and public health interventions to prevent these infections among vulnerable populations. She serves on a number of national and international committees in relation to HIV public health monitoring, prevention and policy development and is an executive trustee for the National AIDS Trust.

Rashida Ferrand is a Reader in International Health at the London School of Hygiene and Tropical Medicine. She is based in Southern Africa where conducts research studies on chronic complications of HIV infection in older children and adolescents, with a particular focus on chronic lung and cardiac disease. Her other research focus is on interventions to improve access to HIV testing and care among adolescents. Rashida is an Honorary Consultant Physician in HIV Medicine at St Bartholomew's Hospital, London.

Julie Fox is an HIV Consultant and Research Lead in HIV Clinical Trials at Guy's and St Thomas' Hospital. Her main research interests are primary HIV infection, PrEP, HIV reservoirs and treatment toxicities. She has an MD in HIV transmission and is a member of the PEP Guidelines committee and the National Research Reservoir Group (CHERUB).

Lucy Garvey is a Consultant in HIV/GU Medicine at St Mary's Hospital, Imperial College Healthcare NHS Trust, London. She completed an MD(Res) at Imperial College in 2011, researching HIV-related brain disease, and her current interests include the management of non-infectious liver disease in HIV-infected adults.

Yvonne Gilleece is a Consultant in HIV and Genitourinary Medicine at Brighton and Sussex University Hospitals NHS Trust, where she is Joint Principal Lead Consultant, and an Honorary Senior Lecturer at Sussex University. She has a special interest in HIV and Women and is Steering Group Lead for SWIFT. She is the Lead for HIV in Fertility, Conception and Pregnancy and also specialises in HIV and Hepatology in Brighton. She is Vice Chair of the BHIVA HIV in Pregnancy guidelines (2014) and the upcoming update of the BHIVA/BASHH Sexual and Reproductive Health guidelines. Yvonne regularly publishes clinical research and presents data nationally and internationally.

Robert James teaches law at Birkbeck, University of London and has researched the law around disease transmission in Europe. He is a patient representative at the Lawson Unit in Brighton and has been involved in treatment advocacy in haemophilia, hepatitis C and HIV for over 20 years. In that time he has injected, swallowed and inhaled mountains of prescribed medicines but still has the same medical conditions he started with.

Patrick Kennedy is a Clinical Senior Lecturer and Consultant Hepatologist at Barts and The London School of Medicine and Dentistry. His research in immune-mediated liver damage and progressive liver disease, particularly in viral hepatitis, is known internationally. He is widely published in the field of hepatology, and has produced novel work redefining disease categorisation and investigating the role of individualised treatment strategies for chronic hepatitis B virus. Patrick has a special interest in liver disease in young people and runs a dedicated young adult hepatology clinic at the Royal London. In addition, he has a specialist expertise in liver disease in elite sports people, including working with premiership football clubs and managing viral hepatitis in professional athletes. Patrick is a member of the viral hepatitis clinical guideline committee for NICE and provides expert opinion for the United Kingdom Advisory Panel on blood-borne viruses.

Saye Khoo is Hon Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital, and Professor in the School of Honorary Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital, and Professor in the School of Biomedical Sciences at the University of Liverpool. Saye's research focuses on the pharmacology of HIV treatment failure and how therapy may be improved by individualised care through an understanding of why drug exposure varies markedly between individuals (and the role of individual characteristics such as weight, gender, host genetics and drug interactions), and identifying vulnerable groups who are at particular risk of failure or toxicity. These studies span bench science, through translational research and into the clinic, and onwards to population-based modelling approaches.

Margaret Kingston has been a Consultant Physician in Genitourinary Medicine at Central Manchester Foundation Trust since 2003. With multi-disciplinary colleagues she established the trust HIV antenatal service in 2006, which manages a complex cohort of patients. Margaret is lead author of the UK guidelines for the management of syphilis (2015 and 2008) and a member of the BASHH Clinical Effectiveness Group and board. Margaret is also Training Programme Director for GUM in her region and Associate Medical Director for Medical Education at her trust.



Charles Lacey is Professor of Medicine at Hull York Medical School, University of York; one of the PIs at the Centre for Immunology and Infection, Department of Biology, University of York; and Honorary Consultant Physician at York Teaching Hospital NHS Trust. Charles previously worked at Imperial College London, and the Leeds General Infirmary. He is a Medical Clinical Academic, looking after patients and conducting research. His research areas include clinical and translational research in HPV, HIV and *Chlamydia trachomatis*.

Sebastian Lucas has sspent three decades as a Histopathologist, studying the clinical pathology of HIV/AIDS in the UK and Africa. His main concerns have been making best use of biopsy and autopsy material to further diagnostics, better patient management, and for research.

Nicola Mackie is a Consultant Physician and Head of Specialty for HIV at Imperial College Healthcare NHS Trust (ICHNT). Her research was in the field of HIV-1 drug resistance and she runs the weekly Virtual Clinic at ICHNT. Nicola is also the Clinical Lead for the HIV Women's Service at Imperial.

Ula Mahadeva graduated in medicine and also obtained an intercalated BSc in Basic Medical Sciences and Molecular Biology from University College London. She entered Histopathology directly after house jobs in medicine and surgery and was a trainee on the North Thames rotation. She obtained the Diploma in Cytopathology before taking up a substantive Consultant post at Guy's and St Thomas' NHS Foundation Trust, where she has been since 2002. Ula's areas of subspecialisation are gastro-intestinal histopathology, gynaecological and non-gynaecological cytopathology, consented and maternal death autopsies, and infectious disease histopathology. She is known within the department and region for her enthusiasm for teaching and training, including helping trainees with preparation for the FRCPath examination, and is an RCPath examiner.

Alexander Margetts has worked as a Clinical Psychologist in HIV and sexual health at Chelsea and Westminster Hospital for the past 7 years, and is also currently the Chair of the British Psychological Society (BPS) Faculty for HIV and Sexual Health. Therapeutically, he works predominately from a Cognitive Behavioural Therapy (CBT) background, and also leads on Neuropsychology for the service. Alongside clinical work, Alexander's role includes service development, supervision, teaching, training and consultation.

Margaret May is Professor of Medical Statistics in the School of Social and Community Medicine, Bristol University. She has co-led the Antiretroviral Therapy Cohort Collaboration (ART-CC) which was set up to examine prognosis for clinical events in patients starting ART in Europe and North America. She has collaborated with UK CHIC to publish on life expectancies of HIV-positive people in the UK, and has an active interest in increasing HIV testing and diagnosis in GP settings. Currently Margaret is investigating how quality of HIV care can be improved by effective monitoring.

Esther McDonnell has worked as an Occupational Therapist in HIV care for over 10 years in both Australia and the UK. This has included acute hospital wards, a long-term care facility for people with HIV-associated dementia, and a community rehabilitation team. She is currently a Specialist Occupational Therapist at Chelsea and Westminster Hospital, and Chair of the Rehabilitation in HIV Association (RHIVA) since 2013. Esther has presented at AIDS 2010 about rehabilitation in ternational contexts, as well as at the World Federation of Occupational Therapists Conference.

Angelina Namiba has over 16 years' experience of working in the HIV sector on initiatives ranging from providing one-to-one support to people living with HIV; to managing service provision; to facilitating, promoting and advocating for the involvement of women living with HIV in forming and informing local and national strategy and policy. She also works with adolescents and young people living with HIV, where she supports them around various issues and coping strategies including HIV Treatment Literacy and general well-being around living with HIV. Angelina is passionate about advocating for the sexual health and reproductive rights of women living with HIV. From 2012–2015 she managed the project From Pregnancy to Baby and Beyond (www.positivelyuk.org/pregnancy_and_beyond.php), which provided information, emotional and practical peer support to pregnant women living with HIV, men living with HIV and their sero-different partners. One of her greatest hopes for the future is for the day when treatment for HIV will be available, affordable and accessible to all those who need it globally.

Mark Nelson is a Consultant Physician at the Chelsea and Westminster Hospital, London. He trained at Jesus College, Cambridge and Westminster Hospital Medical School, where he qualified in 1986. He was appointed Consultant Physician at Chelsea and Westminster in 1991, and is presently the Lead for HIV in Patient and Day Case Care. He is Professor of HIV Medicine at Imperial College Medical School where he is also the Deputy Senior Tutor. Mark has built a large HIV practice with a special interest in HIV in patient care, co-infection with hepatitis B and C, and the clinical utility of new antiretroviral agents. He has published over 500 papers on HIV and hepatitis.



Chloe Orkin is Consultant and Honorary Reader in HIV Medicine at the Royal London Hospital and runs an HIV and HIV/ hepatitis C research unit. She has 70 peer-reviewed publications and co-authored four British HIV Association guidelines: ARVs, Hepatitis, Malignancy and Routine Monitoring. Chloe is External Examiner to the Diploma in HIV Medicine. She is researching ways of implementing HIV and blood-borne virus testing.

Turner Overton serves as the Medical Director of the UAB 1917 HIV Clinic, where his clinical focus involves the improvement of health care delivery to the patients living with HIV and HCV. He is the Site Leader for the AIDS Clinical Trial Unit at UAB and currently serves as the Vice Chair of the End Organ Disease/Inflammation Transformative Science Group for the AIDS Clinical Trials Group. Turner's research interests focus on the long-term complications of HIV, particularly the interface between persistent inflammation and immune activation as they relate to the increasing prevalence of comorbidities seen among HIV-infected persons.

Nikhil Premchand graduated from the medical school at Newcastle University in 2000 and trained in infectious diseases in the Northern Deanery. He became a consultant in 2010 and after working at the RVI until 2012. He moved to this trust to set up a clinical infection service, in addition to working as an acute care physician at North Tyneside and Wansbeck hospitals. Nikhil's particular interests are in HIV and antimicrobial stewardship and he won a 2013 UK and Ireland Gilead Fellowship to develop an HIV Telemedicine service. He was also part of the core team who developed an antibiotic prescribing android and apple app for staff at this trust. Nikhil is the lead for the development of a bone and joint infection service that will consolidate the multi-disciplinary excellence that already exists within the trust to optimise the care for patients with such infections.

lain Reeves is Lead Clinician for HIV at the Homerton Hospital. He is Principal Investigator on a number of research studies and is the chair of the North-East London and Essex Clinical Network for HIV (NELENET).

Alison Rodger is Reader in Infectious Diseases at University College London and Consultant in Infectious Diseases and Director of Public Health at the Royal Free Hospital in London. Alison is a co-author of BHIVA guidelines on Hepatitis Co-infection, Immunisation, Pre-exposure and Post-exposure Prophylaxis. Alison is also the PI on the PANTHEON NIHR programme grant, looking at cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among MSM in the UK.

Gabriel Schembri graduated from the University of Malta as a Medical Doctor in 2001. He moved into Dermato-Venereology from General Medicine in 2006, working with a number of UK-trained physicians and gaining valuable experience in both sexual health and dermatology. Gabriel subsequently moved to the UK and trained in Genitourinary Medicine in Leicester. He is currently employed by the Central Manchester Foundation Trust as a Consultant in Genitourinary Medicine and is also the Research Lead; he also runs a monthly joint HIV renal clinic along with his renal colleagues. Gabriel is a BHIVA trustee and Chair of the BHIVA website working group.

Shema Tariq is a Postdoctoral Clinical Research Fellow at UCL's Centre for Sexual Health and HIV Research and Honorary Consultant at Mortimer Market Centre. Her main area of interest is the reproductive and post-reproductive health of women living with HIV, and she has been closely involved with SWIFT since its inception. Shema's academic experience includes doctoral research exploring engagement with HIV care during pregnancy, and a Fulbright Scholarship to Columbia University to analyse data on late HIV diagnosis in KwaZulu-Natal. Shema is currently leading the PRIME Study, an NIHR-funded study investigating the impact of the menopause on HIV-positive women's health and wellbeing.

Lisa Thorley holds a PhD in Development and Economics and is a social science researcher with interests in development thinking that pertains to women and also HIV, both in the Global North and South. She has recently been involved in the qualitative element of the UK STIGMA Index 2015 project. Moreover, Lisa is an active advocate within the HIV community and is a Director and Trustee for the Terrence Higgins Trust.

Claire Thorne is a Reader in Infectious Disease Epidemiology at the University College London Institute of Child Health. She read Human Sciences at Oxford University and then studied for a Masters at the London School of Hygiene and Tropical Medicine, followed by a PhD in Epidemiology at UCL. Claire's research has a focus on maternal and child health, with a particular emphasis on HIV and viral hepatitis. She has been carrying out research on HIV in pregnant women and children for over 20 years, and leads several HIV cohort studies in Western and Eastern Europe.



Andrew Ustianowski is a Consultant Physician in Infectious Diseases at the North Western Regional Infection Unit, North Manchester General Hospital, which is one of the largest treatment centres for HCV in the UK (and one of the largest for HIV and HBV). He is Chair of the British Viral Hepatitis Group, has been part of guideline writing committees for BHIVA and other bodies, lectures widely on hepatitis, HIV and related topics, and is part of several national and international educational steering groups. He has been a member of the NHS England Clinical Reference Group for Infectious Diseases and for HCV. Andrew graduated from Guy's Hospital, London, and subsequently trained in Infectious Diseases, Tropical Medicine, HIV and General Medicine in the London region.

Laura Waters is a Consultant at The Mortimer Market Centre in London where she is HIV and Hepatitis Service Lead. She was Vice-chair of the 2015 BHIVA ART guidelines and now chairs this group; she is Vice-chair of the BHIVA Conferences subcommittee and Chair of the BASHH HIV SIG. Laura has an MD in ARV simplification and switch and is Principal Investigator for several first-line and switch studies at Mortimer Market.

Shaun Watson has worked in HIV and Palliative Care since 1991 as Ward Manager at Mildmay and Trinity Hospice and since 2003 as a Clinical Nurse Specialist (HIV Community) for City and Hackney, Hammersmith and Fulham and Westminster, London. He is a member of the Executive Board of NHIVNA, Editorial Board of the HIV Nursing Journal and Chair of the Triborough HIV Providers Forum.

FORTHCOMING EVENTS

10th Annual Conference of the Children's HIV Association (CHIVA)

> Friday 27 May 2016 MSHED, Bristol

18th Annual Conference of the National HIV Nurses Association (NHIVNA)

> 29 June–1 July 2016 Manchester Conference Centre

Joint BASHH/BHIVA Diploma in HIV Medicine One-Day Revision Course

Thursday 1 September 2016 South Wing Lecture Theatre, St Thomas' Hospital, London

> 20th Annual Resistance and Antiviral Therapy Meeting

Thursday 15 September 2016 Wellcome Collection Conference Centre, London BHIVA Autumn Conference Including CHIVA Parallel Sessions

13–14 October 2016

preceded by Seventh BHIVA Conference for the Management of HIV/Hepatitis Co-infection in collaboration with BASL and BVHG

> Wednesday 12 October 2016 QEII Centre, London

BHIVA General Medicine for HIV Physicians Course 2016

> Thursday 3 November 2016 (NCVO), London

BHIVA World AIDS Day Event

Wednesday 30 November 2016 London

SPONSORS AND EXHIBITORS

BHIVA MAJOR SPONSORS 2016

Bristol-Myers Squibb Pharmaceuticals Ltd

Uxbridge Business Park, Sanderson Road Middlesex UB8 1DH

Bristol-Myers Squibb

Gilead Sciences Ltd

280 High Holborn, London WC1V 7EE

Janssen

50–100 Holmers Farm Way, High Wycombe Buckinghamshire HP12 4DP



MSD Ltd

Hertford Road, Hoddesdon Hertfordshire EN11 9BU



ViiV Healthcare UK Ltd

Stockley Park West, Uxbridge Middlesex UB11 1BT



BHIVA is grateful to their major sponsors and commercial exhibitors for their continued support. The funds provided by sponsors are used solely for the educational content of the conference and are not allocated to BHIVA's social events.

> Conference Organiser: Mediscript Ltd, 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD T: +44 (0) 20 8369 5380 F: +44 (0)20 8446 9194 E: conferences@bhiva.org



EXHIBITORS

Commercial

Cepheid

Hologic Ltd

Pfizer Ltd

6PM and 6PM Blithe

Affiliated, Educational and Charitable

Children's HIV Association (CHIVA)

Dieticians in HIV/AIDS (DHIVA)

HIV Pharmacy Association (HIVPA)

Mildmay Mission Hospital

National HIV Nurses Association (NHIVNA)

Public Health England

Rehabilitation in HIV Association (RHIVA)

Community

African Health Policy Network

BASELINE

HIV i-Base and UK Community Advisory Board (UK-CAB)

NAM

National AIDS Trust

Naz Project London


Positively UK

Saving Lives

Terrence Higgins Trust

The Sophia Forum

The Sussex Beacon



TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

> Tivicay® 🛡 dolutegravir 50 mg tablets Prescribing Information See Summary of Product Characteristics before prescribing

Indication: HIV in > 12 years and ≥ 40kg as part of combination therapy. Dosing: 50 mg once

Indication: HIV in > 12 years and ≥ 40kg as part of combination therapy. Dosing: 50 mg once daily with or without food if no proven/suspected integrase resistance. 50 mg twice daily with efavirenz, nevirapine, tipranavir/intonavir, etravirine (without boosted PI), carbomazepine, oxcarbozepine, phenytoin, phenobarbital, St John's Wort or rifampicin. Adults with proven/ suspected integrase resistance: 50mg twice daily preferably with food. Elderly: Limited data in 65+ yrs. Caution in severe hepatic impairment. Contraindications: Hypersensitivity to any ingredient. Co-administration with dofetilide. Warnings/precautions: Risk of hypersensitivity reactions. Discontinue dolutegravir and other suspect agents immediately if suspected. Risk of osteonecrosis, immune reactivation syndrome. Monitor LFIs in Hepatitis B/C co-infection and ensure effective Hepatitis B therapy. Caution with metformin: monitor renal function and consider metformin dose adjustment. Use with etravirine requires boosted PI or increased dose ad dolutegravir, Use with Ma/A-containing antaciás, calcium, multivitamins or iron requires dosage

dolutegravir. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. **Pregnancy/lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for full details. Headache, GI disturbance, insomnia, abnormal dreams, depression, dizziness, rash, pruritus, fatigue, elevations of ALT, AST and CPK, hypersensitivity, suicidal ideation or suicide attempt. **Basic NHS costs:** 30 tablets £498.75 EU/1/13/892/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

Tivicay is a registered trademark of the ViiV Healthcare Group of Companies

TIVICAY is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults and adolescents above 12 years of age.

Prescribing Information

Prescribing Information Triumed® ✓ dolutegravir 50mg/dbacavir 600mg/lamivudine 300mg tablets See Summary of Product Characteristics before prescribing. Indication: HIV in over 12 years and ≥ 40kg. Screen for HLA-B'5701 prior to use. Do not use if HLA-B'5701 positive. Dose: one tablet once daily with or without food. *Elderly*: Imited data in 65+ yrs. *Creatinine clearance < 50ml/min or moderate/severe hepatic impairment*. Not recommended. Contraindications: Hypersensitivity to any ingredient. Co-administration with dofetilide. Warnings/precautions: Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B'5701+ or previous suspected abacavir HSR. Stop Triumeg without delay if HSR suspected. Never reintraduce any dolutegravir- or abacavir-ontaining product after suspected HSR. Risks of lactic acidosis, lipodystrophy, immune reactivation syndrome, osteonecrosis. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MIK: minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. (with etravirine doubled and the intervine monitor renal function and consider metromin dose adjustment. Caution with netformin: monitor renal function and consider metromin dose adjustment. Caution with netformin: monitor renal function and consider metromin dese adjustment. Caution with netformin: monitor renal function and consider metromin dese adjustment. Caution with netformin: monitor renal function and consider metroming scene freedrig. Side effects: See SPC for details. Headache, insomnia, sleep/dream disorders. GI disturbance, fatigue, hypersensitivity, anorexia, depression, diziness, somnolence, lethargy, malaise, cough, nasal symptoms, rash, puritus, alopecia, arthralgia, muscle disorders sthemia, fever, elevations of ALT, AST and CPK, blood dyscrasios, suicidal ideation or suicide atthera. Rever, elevations of ALT, AST and CPK, USUTERTING, TEVER, elevations of ALT, AST and CPK, blood dyscrasias, suicidal ideation or suicida attempt, rhabdomyolysis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. **Basic NHS costs:** 30 tablets: 5798.16 EU/1/14/940/001. MA holder: VIV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

POM

Triumeq is a registered trademark of the ViiV Healthcare Group of Companies Date of approval: July 2015 Zinc code: U

Zinc code: UK/TRIM/0037/14(3)

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

POM

Date of approval: August 2015

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA: Freepost, Pharmacoviailance Section, Health Products Regulatory Authority. Farlsfort Terrace Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255



TRIUMEQ and TIVICAY are registered trademarks of the ViiV Healthcare group of companies. ©2015 ViiV Healthcare group of companies All rights reserved

Zinc code: UK/DLG/0055/13(7)